Alkem to launch state-of-the-art technology to treat DFU in India
Category: #tech  By Mateen Dalal  Date: 2022-01-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alkem to launch state-of-the-art technology to treat DFU in India

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India.

The solution would be based on an innovative technology of 4D Bioprinting, which would be used for treating non-healing, deep chronic wounds and is estimated to be launched in the second half of 2022 in the Indian market after receiving the regulatory approvals.

This cutting-edge technology for DFU management possesses high scope of averting amputations in diabetic patients. This technology will be obtainable at reasonable rates to the patients of India at a time when no decisive treatment of DFU is there in India.

At present, India has around 77 million diabetic patients, ranking it to be 2nd highest in the world. DFU (Diabetic foot ulcer) is one of the most common and disturbing complications of diabetes and is restricted as a foot affected by ulceration linked with neuropathy and peripheral arterial disease of the lower limb in a diabetic patient.

Moreover, around 12-15% of diabetic people suffer from DFU at least once in their whole lifetime. 5-24% of this population will finally lead to limb amputation within 6–18 months after the first assessment. The risks of getting limb amputation and foot ulceration increases in contrast to the age and duration of diabetes.

Imperatively, Alkem and Rokit Healthcare Inc. have collaborated to commercialize the technology in India to reduce amputation amongst DFU patients considering the adverse impact of amputation on the quality of patient’s life and the linked economic burden on the healthcare system.

Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd., stated that diabetes is one of the major challenges faced by the healthcare systems in India. The challenge is so massive that diabetic foot ulcers get ignored very often. To address these issues, Alkem and Rokit Healthcare INC have collaborated to bring out a new solution for managing diabetic foot ulcers, Sandeep cited.

Source Credit - https://www.prnewswire.com/in/news-releases/alkem-laboratories-ltd-to-launch-state-of-the-art-technology-for-diabetic-foot-ulcer-management-for-the-first-time-in-india-838015097.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Taco Bell to introduce its first-ever business school for employees
Taco Bell to introduce its first-ever business school for employees
By Mateen Dalal

The fast-food chain has collaborated with the University of Louisville for starting this project Taco Bell, a US-based chain of fast-food restaurants, is reportedly opening its business school with a vision of helping its employees learn the skills ...

Jubilant Foodworks unveils first chain of Popeyes in Bengaluru, India
Jubilant Foodworks unveils first chain of Popeyes in Bengaluru, India
By Mateen Dalal

Jubilant Foodworks Ltd, an Indian food service company, has recently announced unveiling the iconic United States’ Fried Chicken brand-Popeyes in India by inaugurating its first store in Bengaluru, India. For the uninitiated, Popeyes Louisiana...

Affinity to trade Burger King business in Japan & South Korea for $1Bn
Affinity to trade Burger King business in Japan & South Korea for $1Bn
By Mateen Dalal

Affinity Equity Partners, one of the largest dedicated Asian private equity firms, is reportedly planning to sell off its Burger King fast-food businesses in Japan and South Korea, in a deal that can offer more than $1 billion, said a credible source...